



Innovative Medicines Initiative

For immediate release

IMI/OUT/2012-00104

## PRESS RELEASE

### IMI PRESENTS ACHIEVEMENTS AT THE EUROPEAN PARLIAMENT

#### LESSONS LEARNT FOR A FUTURE PUBLIC-PRIVATE PARTNERSHIP IN LIFE SCIENCES UNDER HORIZON 2020

**BRUSSELS, 13 November 2012** – Today Amalia Sartori, Member of the European Parliament and Chair of the Committee on Industry, Research and Energy, is hosting a debate on a future public-private partnership in life sciences under Horizon 2020, based on lessons learnt from the Innovative Medicines Initiative (IMI).

The agenda features high-level speakers including **Amalia Sartori** (European Parliament), **Roch Doliveux** (UCB), **Ruxandra Draghia-Akli** (European Commission), **Magda Chlebus** (European Federation of Pharmaceutical Industries and Associations), **Hans-Georg Eichler** (European Medicines Agency), **Michel Goldman** (Innovative Medicines Initiative) and **representatives of IMI projects and stakeholder groups**.

The debate takes place at a time when important decisions on EU health research are under preparation and against the background of profound changes and challenges in pharmaceutical research & development (R&D). Key issues in this context are:

- Developing innovative drugs is proving increasingly difficult and costly. Some pharmaceutical companies give up on entire disease areas, while many diseases and conditions still lack effective treatments. Is there a way out of this innovation crisis?
- Budgets for pharmaceutical R&D are tighter than ever. Which new business models are needed?
- Are public-private partnerships the way forward? What are the lessons learnt from the IMI experience for Horizon 2020? Would other models offer a better solution?

The debate will be moderated by **Andrew Jack**, **pharmaceuticals correspondent at the Financial Times**.

The event will be followed by a networking cocktail.

#### More information:

- Info on the event: [www.imi.europa.eu/events/2012/09/07/health-research-crossroads](http://www.imi.europa.eu/events/2012/09/07/health-research-crossroads)
- Overview of ongoing IMI projects: [www.imi.europa.eu/content/ongoing-projects](http://www.imi.europa.eu/content/ongoing-projects)
- Project achievements: [www.imi.europa.eu/sites/default/files/uploads/documents/IMIBroch2012Web.pdf](http://www.imi.europa.eu/sites/default/files/uploads/documents/IMIBroch2012Web.pdf)
- Twitter: @IMI\_JU

---

#### Press contact:

Kim De Rijck – External Relations Manager  
Tel: +32 484 89 62 27 - [kim.derijck@imi.europa.eu](mailto:kim.derijck@imi.europa.eu)

---

#### About IMI

IMI is the world's largest public-private partnership in health. IMI is improving the environment for pharmaceutical innovation in Europe by engaging and supporting networks of industrial and academic experts in collaborative research projects. The European Union contributes €1 billion to the IMI research programme, which is matched by in kind contributions worth at least another €1 billion from the member companies of the European Federation of Pharmaceutical Industries and Associations (EFPIA).

The Innovative Medicines Initiative is currently funding 37 projects, many of which are already producing impressive results. The projects all address major bottlenecks which will accelerate the development of safer and more effective treatments for patients.

More info: [www.imi.europa.eu](http://www.imi.europa.eu)

